# US 2012/0252851 A1 · Delivery system for sustained release of a calcium-channel blocking agent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252851 A1
- Document ID: US20120252851A1
- Status: Published application
- Kind: A1
- Application number: 13/500,013
- Filed: 2010-10-05
- Published: 2012-10-04
- Earliest claimed: 2009-10-06
- Assignees: Peter Holig; Jorg Breitenbach
- Inventors: Jorg Breitenbach; Bernd Liepold; Didier R. Lefebvre; Steffen Bossmann; Benedikt Steitz; Peter Hölig
- Web page: https://patentgrep.com/patent/US20120252851A1

## CPC

- A61K 31/216: of acids having aromatic rings, e.g. benactizyne, clofibrate
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 9/146: {with organic macromolecular compounds}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A delivery system for sustained release of a calcium-channel blocking agent is adapted for introduction in the cerebrospinal fluid of a subject. The delivery system comprises a solid dispersion product of a calcium-channel blocking agent in a mixture of a (i) first poly(lactide-co-glycolide) having a molecular weight distribution centered around a first number average molecular weight Mn1 and a (ii) second poly(lactide-co-glycolide) having a molecular weight distribution centered around a second number average molecular weight Mn2, wherein Mn1 is in the range of from 2000 to 3000 g/mol and the ratio of Mn1/Mn2 is from 1.8 to 3.5. The delivery system is deposited in the vicinity of or adjacent to a blood vessel showing vasospasm or suspected of developing vasospasm.

## Claims

### Claim 1

Delivery system for sustained release of a calcium-channel blocking agent, adapted for introduction in the cerebrospinal fluid of a subject, comprising a solid dispersion product of a calcium-channel blocking agent in a mixture of a (i) first poly(lactide-co-glycolide) having a molecular weight distribution centered around a first number average molecular weight Mn1 and a (ii) second poly(lactide-co-glycolide) having a molecular weight distribution centered around a second number average molecular weight Mn2, wherein Mn1 is in the range of from 2000 to 3000 g/mol and the ratio of Mn1/Mn2 is from 1.8 to 3.5.

### Claim 2 (depends on 1)

Delivery system according to claim 1, wherein the weight ratio of the first poly(lactide-co-glycolide) and the second poly(lactide-co-glycolide) is from 10:1 to 1:1.5.

### Claim 3 (depends on 1)

Delivery system according to claim 1, wherein the lactate:glycolate molar ratio in the first poly(lactide-co-glycolide) is from 45:55 to 55:45.

### Claim 4 (depends on 1)

Delivery system according to claim 1, wherein the lactate:glycolate molar ratio in the second poly(lactide-co-glycolide) is from 45:55 to 55:45.

### Claim 5 (depends on 1)

Delivery system according to claim 1, wherein the calcium-channel blocking agent constitutes 1 wt-% to 25 wt-% of the total weight of the solid dispersion product.

### Claim 6 (depends on 1)

Delivery system according to claim 1, wherein the calcium-channel blocking agent is molecularly dispersed in the monophasic mixture.

### Claim 7 (depends on 1)

Delivery system according to claim 1, wherein the calcium-channel blocking agent is nicardipine, a pharmaceutically acceptable salt, hydrate or solvate thereof.

### Claim 8 (depends on 7)

Delivery system according to claim 7, showing an in vitro release profile characterized in that
4.5% to 8.5% of the total amount of nicardipine is released after 1 day,
10% to 20% of the total amount of nicardipine is released after 3 days, and
25% to 36%, of the total amount of nicardipine is released after 7 days;
when a delivery system containing the equivalent of 4 mg nicardipine is placed in a dissolution medium of phosphate buffered saline, pH 7.4, and 0.1 vol.-% polysorbate 80, at 37° C. with shaking at 60 strokes per minute.

### Claim 9 (depends on 1)

Delivery system according to claim 1, for the treatment or prevention of brain vasospasm.

### Claim 10 (depends on 1)

Method of treatment or prevention of brain vasospasm in a subject by depositing a delivery system according to claim 1 in the cerebrospinal fluid of the subject.

### Claim 11 (depends on 10)

Method of treatment or prevention according to claim 10, wherein the delivery system is deposited in the vicinity of or adjacent to a blood vessel showing vasospasm or suspected of developing vasospasm.

### Claim 12 (depends on 1)

Method for the preparation of a delivery system according to claim 1, comprising preparing a melt of the first poly(lactide-co-glycolide), the second poly(lactide-co-glycolide) and the calcium-channel blocking agent and allowing the melt to solidify.

### Claim 13 (depends on 12)

Method according to claim 12, comprising the steps of:
a) providing a mixture of the first poly(lactide-co-glycolide), the second poly(lactide-co-glycolide) and the calcium-channel blocking agent,
b) increasing the temperature of the mixture to a first temperature T1 and maintaining the mixture at the temperature T1 in order to melt the first and the second poly(lactide-co-glycolide) and to disperse the calcium-channel blocking agent therein,
c) decreasing the temperature to a second temperature T2 and maintaining the mixture at the temperature T2 in order to adjust the viscosity of the mixture to a viscosity suitable for extrusion, and
d) forcing the mixture through a die.
